Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 2/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | NSD2 | O96028 | 2/20 | 0.37 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | EGLN2 | Q96KS0 | 3/20 | 0.36 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.36 |
| ▸ | AR | P10275 | 3/20 | 0.36 |
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.35 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | HTR2A | P28223 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL20840172 | 0.98 | LOXL2 (0.45) | LOXL2CYP2A6ALDH1A1NSD2KDM5A | |
| SCHEMBL18934890 | 0.84 | LOXL2 (0.47) | LOXL2CYP2A6ALDH1A1NSD2FFAR1 | |
| SCHEMBL2153680 | 0.83 | CYP2A6 (0.44) | LOXL2CYP2A6ALDH1A1KDM5AKDM4C | |
| SCHEMBL2154771 | 0.83 | CYP2A6 (0.44) | LOXL2CYP2A6ALDH1A1KDM5AKDM4C | |
| SCHEMBL12763619 | 0.82 | CYP2A6 (0.48) | LOXL2CYP2A6ALDH1A1KDM5AKDM4C | |
| SCHEMBL21995424 | 0.80 | CYP2A6 (0.41) | LOXL2CYP2A6ALDH1A1KDM5AKDM4C | |
| SCHEMBL22954538 | 0.80 | LOXL2 (0.37) | LOXL2 | |
| SCHEMBL20864209 | 0.80 | CYP2A6 (0.41) | LOXL2CYP2A6ALDH1A1KDM5AKDM4C | |
| SCHEMBL3715551 | 0.80 | CYP2A6 (0.41) | LOXL2CYP2A6ALDH1A1KDM5AKDM4C | |
| SCHEMBL410177 | 0.80 | CYP2A6 (0.41) | LOXL2CYP2A6ALDH1A1KDM5AKDM4C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110234630-B | Phenylimidazolines having aminomethyl groups Compound or salt thereof and process for producing the same | 三菱瓦斯化学株式会社 | 2023-02-03 | — | — | CN | claimed |
| WO-2022271679-A1 | SOS1 INHIBITORS | Mirati Therapeutics, Inc. (US) | 2022-12-29 | — | — | WO | disclosed |
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | JONES BENJAMIN (US) | 2020-09-03 | — | — | US | disclosed |
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | JONES BENJAMIN (US) | 2020-09-03 | — | — | US | disclosed |
| EP-3676251-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | Takeda Pharmaceutical Company Limited (JP) | 2020-07-08 | — | — | EP | disclosed |
| WO-2019060850-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-03-28 | — | — | WO | disclosed |
| WO-2019060850-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES USEFUL AS HIF PROLYL HYDROXYLASE INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2019-03-28 | — | — | WO | disclosed |
| CN-105143201-B | Benzyl amine derivative | 卡尔维斯塔制药有限公司 | 2019-02-22 | — | — | CN | disclosed |
| US-9834513-B2 | Benzylamine derivatives | Kalvista Pharmceuticals Limited (GB) | 2017-12-05 | — | — | US | disclosed |
| US-20170253561-A1 | Benzylamine Derivatives | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-09-07 | — | — | US | disclosed |
| EP-2943483-A1 | BENZYLAMINE DERIVATIVES | Kalvista Pharmaceuticals Limited (GB) | 2015-11-18 | — | — | EP | disclosed |
| WO-2014108679-A1 | BENZYLAMINE DERIVATIVES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-07-17 | — | — | WO | disclosed |
| WO-2014020350-A1 | PAR2 RECEPTOR ANTAGONISTS | PROXIMAGEN LIMITED (GB) | 2014-02-06 | — | — | WO | disclosed |
| CN-100379722-C | Compounds | ASTRA ZENECA LTD (SE) | 2008-04-09 | — | — | CN | disclosed |
| EP-1036061-B1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 2003-09-24 | — | — | EP | disclosed |
| US-6337394-B2 | N-ACYL-HETEROCYCLE-CARBOXYAMIDES THAT ARE N-SUBSTITUTED WITH AMIDINO-SUBSTITUTED RINGS; COMPETITIVE INHIBITORS OF THROMBIN; ANTICOAGULANTS | ASTRAZENECA AB (SE) | 2002-01-08 | — | — | US | disclosed |
| US-20010046981-A1 | COMPOUNDS | ASTRA AKTIEBOLAG (SE) | 2001-11-29 | — | — | US | disclosed |
| CN-1284063-A | Compounds | ASTRA ZENECA LTD (SE) | 2001-02-14 | — | — | CN | disclosed |
| EP-1036061-A1 | NEW COMPOUNDS | AstraZeneca AB (SE) | 2000-09-20 | — | — | EP | disclosed |
| WO-1999029664-A1 | NEW COMPOUNDS | ASTRAZENECA AB (SE) | 1999-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277262-A1 | N-(CYANO-SUBSTITUTED BENZYL OR PYRIDINYLMETHYL)-3-HYDROXYPICOLINAMIDE DERIVATIVES | P4HA1, HRH3, HRH1 | LOXL2 1915/4885CYP2A6 114/4885ALDH1A1 1144/4885 |
| US-20010046981-A1 | COMPOUNDS | F2, SERPINC1, SERPINB1 | LOXL2 1948/4885CYP2A6 1226/4885ALDH1A1 2984/4885 |
| US-20170253561-A1 | Benzylamine Derivatives | BDKRB1, BDKRB2, KLKB1 | LOXL2 2032/4885CYP2A6 1945/4885ALDH1A1 2364/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.